Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
about
ET(B) receptor-deficient rats exhibit reduced contraction to ET-1 despite an increase in ET(A) receptorsThe effects of ethnic discrimination and socioeconomic status on endothelin-1 among blacks and whites.Activation of endothelin A receptors contributes to impaired responsiveness of renal mechanosensory nerves in congestive heart failureEvaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.Natakalim improves post-infarction left ventricular remodeling by restoring the coordinated balance between endothelial function and cardiac hypertrophy.Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents.Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failurePresent and future pharmacotherapy for heart failure.Current and emerging therapy for primary pulmonary hypertension.Assessment of endothelial damage and dysfunction: observations in relation to heart failure.Modulation and roles of the endothelins in the pathophysiology of pulmonary embolism.Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study.Free radicals and antioxidants in cardiovascular diseases.Endothelial function and its assessment.Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization.Endothelin-1, aging and hypertension.Endothelin downregulates SERCA2 gene and protein expression in adult rat ventricular myocytes: regulation by pertussis toxin-sensitive Gi protein and cAMP.Role of paraventricular nucleus vasopressin V1A receptors in the response to endothelin 1 activation of the subfornical organ in the rat.Assessment of endothelial dysfunction.New drugs and devices in the pipeline for heart failure with reduced ejection fraction versus heart failure with preserved ejection fraction.Involvement of Cytokines in the Pathogenesis of Salt and Water Imbalance in Congestive Heart Failure.Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients.Inhibition of in vivo constriction of fetal ductus arteriosus by endothelin receptor blockade in rats.Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin.Endothelin receptor antagonists in heart failure--a refutation of a bold conjecture?Antagonism of endothelin-1 inhibits hypoxia-induced apoptosis in cardiomyocytes.Contribution of endothelin to coronary vasomotor tone is abolished after myocardial infarction.Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.Central endothelin: effects on vasopressin and the arterial baroreflex in doxorubicin heart failure rats.Common genetic variation in the type A endothelin-1 receptor is associated with ambulatory blood pressure: a family study.Neurohormonal activation in acute heart failure: results from VERITAS.The value of B-type natriuretic peptide and big endothelin-1 for detection of severe pulmonary hypertension in heart transplant candidates.
P2860
Q28582070-10C2E938-73F3-43C5-B0DC-A0F1D15C7689Q33611318-7D1CDABB-9833-4004-A1AC-7F3C2EBDA842Q34007743-11DB5F5D-3D4A-48EB-8498-CAF13B668872Q34241396-9B037F8C-A721-4C84-B90E-685EECF877F6Q34350298-ED3CF111-4582-4299-ACC1-5B1D631E7722Q34496108-05544AFD-57EE-4A72-8791-F675E4BF3775Q34557833-FAD0AADC-5D6B-45A8-8898-CCF05471AD49Q34706912-85D26538-A7FE-4BBD-978D-B8D1C5CFA2DEQ34796981-1EA7CBEB-86D7-488D-A2CD-7719AD4E679BQ35090254-664DB431-6B8A-4FD1-AAAC-D9B9F19413CBQ35168407-FFDDA83D-1E56-4A22-9AB8-A6983ED5F315Q35770795-0B21C32D-0408-44A7-ACD7-3F42B84FE3E7Q36050521-CF1B167C-0639-48D3-8FB8-EC46A8511E01Q36300017-A4393037-43A3-47D7-8A78-FF68828AE3A9Q36717615-C4937FFB-3523-4939-8AD5-58CDCA90F05DQ36726832-B907CD6C-770C-4EB7-9CAF-C972B557E8AFQ37138937-249CEA6F-4578-48B6-B891-60D4D58BFA50Q37346212-5C277BBC-3961-425F-BB64-A994ACD08855Q37732250-3C7490CE-144C-4C22-A051-12EAABA6473EQ38248398-B83B7516-1BC8-4604-AA8A-914B57710C02Q38695069-85FB5970-057C-400E-BFDA-0D8308AED402Q44052018-B9BCB5AD-3AA8-44E2-BB39-4DD6B38FD9AFQ44321537-8DE918F6-4970-420F-A866-C87FE8DBB606Q44405797-6C6FD456-F85D-4BFB-BC33-7C7AA80693E6Q44551628-99724703-A9BC-4540-9193-4D3CDFCCCA56Q44679492-36B17E43-9903-4844-B184-979B79EB23F3Q45086319-3BDBF519-3B21-4202-8A79-5763786C6DBEQ45120606-9E26B572-F47C-4045-B778-FAA9BAC795D0Q46564530-7A745054-6236-4F4E-9705-7926A589BA64Q47993405-4CFCCC55-2C24-4036-9396-2ADA4E55FF46Q48903573-CD80E5F7-8AF8-40D8-AD9F-54DB07B5C6A4Q53855638-986DF104-EA4C-4F1E-9089-3A91BC4886AB
P2860
Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Endothelin receptor antagonist ...... utic principle for the future?
@ast
Endothelin receptor antagonist ...... utic principle for the future?
@en
Endothelin receptor antagonist ...... utic principle for the future?
@nl
type
label
Endothelin receptor antagonist ...... utic principle for the future?
@ast
Endothelin receptor antagonist ...... utic principle for the future?
@en
Endothelin receptor antagonist ...... utic principle for the future?
@nl
prefLabel
Endothelin receptor antagonist ...... utic principle for the future?
@ast
Endothelin receptor antagonist ...... utic principle for the future?
@en
Endothelin receptor antagonist ...... utic principle for the future?
@nl
P2093
P1476
Endothelin receptor antagonist ...... utic principle for the future?
@en
P2093
F T Ruschitzka
L E Spieker
T F Lüscher
P304
P356
10.1016/S0735-1097(01)01210-4
P407
P577
2001-05-01T00:00:00Z